{"id":"W4392091243","doi":"10.1200/jco.23.01601","title":"First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":216,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Princess Margaret Cancer Centre","funders":"National Cancer Institute; Ono Pharmaceutical; Bristol-Myers Squibb","keywords":"Medicine; Nivolumab; Gastroesophageal Junction; Esophageal adenocarcinoma; Chemotherapy; Internal medicine; Gastric adenocarcinoma; Adenocarcinoma; Gastroenterology; Phases of clinical research; Oncology; Surgery; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002148737,0.0002108892,0.001593832,0.000184994,0.0000799874,0.00002193206,0.0002199631,0.0002344867,0.0001499995],"category_scores_gemma":[0.001157854,0.0001330848,0.0009635846,0.0002994601,0.0002357109,0.000147494,0.00007604214,0.000687736,0.000002588616],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002027753,"about_ca_system_score_gemma":0.001002282,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001052585,"about_ca_topic_score_gemma":0.00002239279,"domain_scores_codex":[0.9966044,0.0001277664,0.002255099,0.0002866002,0.0004171421,0.0003089585],"domain_scores_gemma":[0.9969183,0.001112368,0.00117754,0.0002415215,0.0003106041,0.0002396235],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6242429,0.002301527,0.01778634,0.0006832978,0.00232082,0.0004733951,0.0004993078,0.0001202661,0.0001605029,0.0005213005,0.04598768,0.3049027],"study_design_scores_gemma":[0.8275675,0.05314076,0.04931566,0.0002866388,0.002416318,0.0003500394,0.0002561992,0.001875253,0.0001791635,0.0006985808,0.06374113,0.0001727563],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9700074,0.002509456,0.004901228,0.01322066,0.007785451,0.001305084,0.0000137768,0.00002658953,0.0002303204],"genre_scores_gemma":[0.9885749,0.001030968,0.002772165,0.0009320913,0.003386818,0.00002026683,0.000004479525,0.0000339667,0.003244342],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3047299,"threshold_uncertainty_score":0.5427039,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06358621870465926,"score_gpt":0.4120272378043416,"score_spread":0.3484410190996823,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}